OptiBiotix Health Plc (LON:OPTI) were the subject of an article written by G A Chester on the fool.co.uk website yesterday in which it says its growth will be largely determined by their own progress rather than by the macroeconomic background. Which is understandable when you consider that it has a portfolio of patents on compounds that change the way that microbes in the body work and interact is and that it is receiving considerable interest from some big players. The site mentions that Optibiotix have an option agreement “with a multinational consumer goods company” (rumoured to be US giant Procter & Gamble) and that a foot note in a recent announcement states that KSF is “an investee of Kainos Capital, with a responsibility for the SlimFast brand in the UK, Ireland and Germany”.
We caught up with OptiBiotix Health Plc CEO Stephen OHara, who said ‘ This article from Motley Fool identifies companies, like OptiBiotix, whose growth prospects will be largely determined by their own progress, rather than by the macroeconomic background, providing a potentially safer bet in a volatile market. As recent deals with CSL and KSF demonstrate as we validate our technology platforms we are seeing growing interest from industry partners. We now have commercial deals across all our platforms Importantly, these deals are bringing global marketing, sales, and distribution expertise to OptiBiotix’s platforms creating opportunities for multiple revenue streams across different territories and markets’.
